Adding to the roaster of COVID-19 vaccines, Johnson & Johnson announced a slightly different vaccine that involves a one-dose inoculation developed by its vaccines division, Janssen Pharmaceuticals. The trials have shown to be 66% protective against moderate to severe Covid infection in a multicountry study. The critical part of the study shows it was 85% effective in protecting against severe disease.
Special Thanks
- René Najera, DrPH. Senior Epidemiologist
- Dr. Ralph J. DiClemente, Chair NYU School of Social and Behavioral Sciences
- Dr Neurofourier
- Puneet Singh, PKS Law Group
- Dr Maureen Miller, PhD, Epidemiologist, Columbia University
- Dr John Mattison, Arsenal Capital Partners
- Edward Nirenberg
- Resolve to Save Lives
- X-Prize
- Robert Holdheim
- Vivienne Ming, Socos Lab
- Natalie Sarkic-Todd, TheBattleground.eu
- Jeff Chertack, Gates Foundation
- Mrigank Shail MD, WHO
- Dr Obinna Onyekwena, Global Fund
- Dr. Glennis Mehra, Biolabs@NYULangone
- Jane Sloan, Asia Foundation
- Pandemic Action Network
- Simon Lester, World Trade Law
- Jas Charanjiva
- Reuben Abraham, IDFC
Covidpedia Labs offers public health information on the COVID 19 pandemic for your general knowledge. This information does not replace written law or professional medical advice, diagnosis, or treatment. It is intended to raise awareness on COVID-19 for public use and consumption. If you have questions from the information you have read on this site regarding a medical condition, access to medicine and/or vaccines, always seek the professional advice of a doctor or other qualified health professionals. All copyrighted content is labeled. If you’d like to share copyrighted content, contact the owner of that material.